Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under... Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. Mehr anzeigen
-- Presentations to be webcast on www.exelixis.com -- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor...
Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.47 | 4.20120034296 | 34.99 | 36.73 | 34.99 | 1767159 | 36.0918534 | CS |
| 4 | 3.02 | 9.03110047847 | 33.44 | 36.73 | 33.34 | 2197960 | 35.15128427 | CS |
| 12 | 10.78 | 41.9781931464 | 25.68 | 36.73 | 25.12 | 2134545 | 30.37043096 | CS |
| 26 | 16.15 | 79.5174790743 | 20.31 | 36.73 | 20.14 | 1915092 | 27.2051384 | CS |
| 52 | 15.46 | 73.619047619 | 21 | 36.73 | 19.2 | 2062448 | 24.64358154 | CS |
| 156 | 19.26 | 111.976744186 | 17.2 | 36.73 | 14.87 | 2329679 | 20.64898779 | CS |
| 260 | 19.94 | 120.702179177 | 16.52 | 36.73 | 13.67 | 2383079 | 20.79201327 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
